This Trial is a Randomised, Multicentre, Investigator-blind, Vehicle and Comparator-controlled, Parallel-group Trial With the Purpose of Evaluation Efficacy, Safety and Convenience of the MC2-01 Cream

Exclusion Criteria

• •Current diagnosis of unstable forms of psoriasis
• •Other inflammatory skin disease in the treatment area that may confound the evaluation of the psoriasis vulgaris
• •Presence of pigmentation, extensive scarring, pigmented lesions or sunburn in the treatment areas
• •Planned excessive or prolonged exposure to either natural or artificial sunlight
• •History of hypersensitivity to any component of the test product or reference product
• •Current or past history of hypercalcemia, vitamin D toxicity, severe renal insufficiency, or severe hepatic disorders
• •Systemic treatment with biological therapies
• •Use of systemic treatments that suppress the immune system and other systemic chemotherapeutic antineoplastic therapy within 4 weeks prior to Visit 1/Baseline and during the trial
• •Use of phototherapy within 4 weeks prior to Visit 1/Baseline and during the trial
• •Use of topical treatments except for emollients and non-medicated shampoos, with a possible effect on psoriasis within 2 weeks prior to Visit 1/Baseline
• •Presence of infections in the treatment area (bacteria, viruses, parasites or fungi) or skin manifestations of atrophic skin, atrophic striae, skin vein fragility, ichthyosis, acne vulgaris, acne rosacea, rosacea, ulcers and wound in the treatment area
• •Known Human Immunodeficiency Virus (HIV) infection
• •Have any chronic or acute medical condition that may pose a risk to the safety of the subject, or may interfere with the assessment of safety or efficacy in this trial
• •Initiation of, or expected changes to, concomitant medication that may affect psoriasis